

**EFFECTIVE DATE:** 07|01|2018

**POLICY LAST UPDATED:** 05|15|2018

## OVERVIEW

Parsabiv is a calcium-sensing receptor agonist indicated for Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section.

## MEDICAL CRITERIA

Parsabiv (etelcalcetide) will be approved when ALL of the following are met:

1. The patient has a diagnosis of secondary hyperparathyroidism with chronic kidney disease  
**AND**
2. The patient is on hemodialysis  
**AND**
3. The patient's corrected serum calcium is at or above the lower limit of the normal range  
**AND**
4. The patient has a pre-treatment or current intact PTH (iPTH) level of greater than or equal to 300 pg/mL  
**AND**
5. The patient does not have any one of the following limitations to the use of Parsabiv:
  - a. Parathyroid carcinoma **OR**
  - b. Primary hyperparathyroidism**AND**
6. ONE of the following:
  - a) The patient's medication history includes previous use of a prerequisite agent (Sensipar (cinacalcet) and had an inadequate response to treatment (inadequate reduction in IPTH) **OR**
  - b) The patient has a documented intolerance, FDA labeled contraindication, or developed hypocalcemia from treatment

**Length of Approval:** 12 months.

## PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare

## POLICY STATEMENT

### BlueCHiP for Medicare

Etelcalcetide (Parsabiv) is covered when all of the criteria have been met.

## COVERAGE

Benefits may vary between groups and contracts. Please refer to the Evidence of Coverage for applicable physician administered drug benefits/coverage.

## BACKGROUND

Secondary hyperparathyroidism (HPT) is a frequent complication in patients with chronic kidney disease (CKD). It is characterized by elevated phosphorus and vitamin D deficiency. The implications of untreated

secondary HPT include renal bone disease, weakness, fractures, bone and muscle pain, as well as avascular necrosis.

Management of secondary HPT in patients with dialysis involves dietary phosphate restriction and use of a combination of phosphate binders (e.g. calcium acetate, Renagel, Renvela, Fosrenol), vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol), and/or calcimimetics (e.g. Sensipar, Parsabiv). The goal of therapy is to maintain serum level of phosphorus between 3.5 and 5.5 mg/dL.

#### **CODING**

##### **BlueCHiP for Medicare**

The following code is covered when the criteria are met:

**J0606** Injection, etelcalcetide, 0.1 mg

#### **RELATED POLICIES**

Prior Authorization of Drugs

#### **PUBLISHED**

Provider Update, June 2018

Provider Update, March 2018

#### **REFERENCES:**

1. Parsabiv prescribing information. Amgen. April 2017

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

